One of the biggest challenges with hemangiosarcoma is that by the time symptoms show up, the cancer is already in its late stages. That often means the only option left is palliative care. Thankfully, researchers are making major progress in early detection, which could lead to faster treatment and better outcomes. But until now, there hasn’t been a test sensitive enough to catch these aggressive canine cancers at their most treatable stages.
Calviri is a biotech company focused on developing diagnostic tools for early cancer detection in both dogs and humans, as well as vaccines for treatment and prevention. They recently published a study in the American Journal of Veterinary Research highlighting their new breakthrough blood test.
This test can detect five of the most common dog cancers at Stage 1: hemangiosarcoma, osteosarcoma, mast cell tumors, lymphoma, and soft tissue sarcomas. The researchers spent four years collecting samples to develop this test, studying 283 dogs – some with cancer diagnoses and others that were cancer-free.
The test works by analyzing a small blood sample placed on special peptide chips – cutting-edge technology developed by Calviri. Using two different scanning methods, it detects cancer with high accuracy: the simpler model catches 68-98% of Stage 1 cancers, while the more complex model identifies 60-88%. Most importantly, it proves that even early-stage cancers leave clear detectable traces in a dog’s blood.
Based on these results, Calviri will launch StageOne Plus at a limited number of veterinary clinics this August, with plans to expand availability as testing capacity increases. The goal is to make this an affordable diagnostic tool for dogs five years or older during their yearly wellness checkups.
This blood test – which Calviri aims to bring to as many clinics as possible – represents a major breakthrough in canine cancer detection. Ultimately, it could transform outcomes for dogs facing hemangiosarcoma and other aggressive cancers.
